Gainers
- Radiopharm Theranostics (NASDAQ:RADX) stock rose 106.3% to $8.79 during Monday's pre-market session. The company's market cap stands at $33.1 million.
- Greenwich LifeSciences (NASDAQ:GLSI) stock increased by 38.58% to $14.87. The company's market cap stands at $143.4 million.
- Immunome (NASDAQ:IMNM) shares increased by 22.63% to $24.0. The market value of their outstanding shares is at $1.7 billion.
- ENvue Medical (NASDAQ:FEED) shares increased by 20.48% to $4.94. The company's market cap stands at $4.4 million.
- Abpro Hldgs (NASDAQ:ABP) shares rose 19.76% to $7.03. The market value of their outstanding shares is at $15.9 million.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 19.15% to $5.66. The market value of their outstanding shares is at $2.9 million.
Losers
- Tiziana Life Sciences (NASDAQ:TLSA) stock declined by 14.1% to $1.53 during Monday's pre-market session. The company's market cap stands at $207.9 million.
- CapsoVision (NASDAQ:CV) stock decreased by 13.47% to $11.12. The company's market cap stands at $601.9 million.
- BeyondSpring (NASDAQ:BYSI) shares decreased by 9.48% to $1.91. The company's market cap stands at $86.7 million.
- Atossa Therapeutics (NASDAQ:ATOS) stock fell 9.1% to $0.75. The market value of their outstanding shares is at $106.5 million.
- VivoSim Labs (NASDAQ:VIVS) shares decreased by 9.01% to $2.02. The company's market cap stands at $5.7 million.
- Akanda (NASDAQ:AKAN) stock decreased by 8.52% to $0.86. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
AKANAkanda Corp
$0.8571-8.82%
ATOSAtossa Therapeutics Inc
$0.7295-11.6%
BDRXBiodexa Pharmaceuticals PLC
$5.5015.8%
BYSIBeyondSpring Inc
$1.93-8.53%
CVCapsoVision Inc
$10.93-14.9%
FEEDENvue Medical Inc
$4.202.44%
GLSIGreenwich LifeSciences Inc
$13.1522.6%
IMNMImmunome Inc
$24.9127.3%
RADXRadiopharm Theranostics Ltd
$15.13255.2%
TLSATiziana Life Sciences Ltd
$1.875.06%
VIVSVivoSim Labs Inc
$2.02-9.01%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

